Jupiter Life Line Hospitals quarterly results

Q2 FY27 · Jul–Sep 2026

₹ crore	Q2 FY27	Q2 FY26	Change
Revenue	456	394	+16.0%
EBITDA	107	92.2	+15.8%
EBITDA margin	23.4%	23.4%	0.0 pts
Profit before tax	75.1	74.2	+1.2%
Net profit	56.4	57.5	−1.9%
EPS	₹1.72	₹8.75	−80.3%

Every quarter

₹ crore except per share

Tap a line for its trend	Q2 FY27Sep 2026	Q1 FY27Jun 2026	Q4 FY26Mar 2026	Q3 FY26Dec 2025	Q2 FY26Sep 2025	Q1 FY26Jun 2025	Q4 FY25Mar 2025	Q3 FY25Dec 2024	Q2 FY25Sep 2024	Q1 FY25Jun 2024	Q4 FY24Mar 2024	Q3 FY24Dec 2023

Expenses
	456	411	388	365	394	348	327	321	323	287	290	273
	10.5	10.6	9.1	9.1	11.3	12.9	7.0	8.3	9.4	8.4	9.0	8.1
	467	422	397	374	405	360	334	329	332	295	299	281
	84.3	79.7	76.8	76.7	74.5	68.7	59.5	60.3	59.6	53.6	53.4	48.4
	2.2	0.4	−3.1	−7.7	−0.8	−0.4	1.7	−1.5	0.4	−3.3	−0.6	−0.3
	81.3	74.5	67.7	63.6	63.2	59.4	53.8	55.5	53.9	51.3	51.5	50.1
	13.8	12.9	9.0	7.5	7.8	8.3	5.6	2.8	1.1	1.1	0.9	1.0
	28.5	26.4	23.3	21.7	21.5	21.2	17.6	14.0	14.4	11.0	10.4	10.7
	182	177	157	149	164	142	134	131	134	122	124	113
	392	371	331	311	331	299	272	262	263	235	240	222
	107	79.3	89.2	83.4	92.2	78.1	78.3	75.0	75.0	63.9	62.3	61.9
	78.4	52.8	65.9	61.7	70.8	56.9	60.6	61.0	60.6	52.9	51.9	51.2
Profit
	75.1	50.6	66.0	63.3	74.2	61.5	62.1	66.6	68.9	60.1	59.9	58.2
	0.0	0.0	0.0	−6.4	0.0	0.0	0.0	0.0	0.0	0.0	2.3	−0.2
	75.1	50.6	66.0	56.9	74.2	61.5	62.1	66.6	68.9	60.1	62.2	58.1
	16.5	13.2	9.6	15.5	20.2	18.3	14.0	13.7	18.2	14.6	16.3	13.8
	2.2	−0.1	7.6	−1.0	−3.5	−0.6	3.2	0.4	−0.8	0.9	0.7	0.6
	18.7	13.0	17.3	14.4	16.7	17.7	17.2	14.0	17.4	15.5	16.9	14.4
	56.4	37.5	48.8	42.5	57.5	43.9	44.9	52.5	51.5	44.6	45.3	43.7
	56.4	37.5	48.8	42.5	57.5	43.9	44.9	52.5	51.5	44.6	45.3	43.7
	−0.9	0.0	1.9	0.0	0.0	0.0	−1.2	0.0	0.0	0.0	−0.9	0.0
	55.5	37.5	50.7	42.5	57.5	43.9	43.7	52.5	51.5	44.6	44.4	43.7
	56.2	37.5	50.6	42.6	57.4	43.8	44.9	—	51.5	44.6	—	—
	0.2	0.0	0.1	−0.1	0.1	0.0	0.0	—	0.0	0.0	0.0	—
Per share
	₹1.72	₹5.72	₹7.66	₹6.49	₹8.75	₹6.69	₹6.84	₹8.01	₹7.86	₹6.80	₹6.49	₹6.56
	₹1.72	₹5.72	₹7.66	₹6.49	₹8.75	₹6.69	₹6.84	₹8.01	₹7.86	₹6.80	₹6.49	₹6.56
Other comprehensive income — detail
	−0.9	0.0	1.9	0.0	0.0	—	−1.2	—	—	—	—	—
	−0.9	—	—	—	—	—	−1.6	—	—	—	−0.9	0.0
	0.0	0.0	−1.9	0.0	0.0	—	−0.4	—	—	—	—	—
	55.3	37.5	50.6	42.6	57.4	43.8	—	—	51.5	44.6	—	—
	0.2	0.0	0.1	−0.1	0.1	0.0	—	—	0.0	0.0	—	—
Per share — as-filed variants
	₹1.72	₹5.72	₹7.66	₹6.49	₹8.75	₹6.69	₹6.84	₹8.01	₹7.86	₹6.80	₹6.49	₹6.56
	₹1.72	₹5.72	₹7.66	₹6.49	₹8.75	₹6.69	₹6.84	₹8.01	₹7.86	₹6.80	₹6.49	₹6.56
Derived — gross profit (revenue − materials − purchases − Δ inventories)
	370	331	314	296	320	279	266	262	263	237	238	224
	81.0%	80.5%	81.0%	81.1%	81.3%	80.3%	81.3%	81.7%	81.4%	82.5%	81.8%	82.3%
Adjusted (ex-exceptional items) — derived
	75.1	50.6	66.0	63.3	74.2	61.5	62.1	66.6	68.9	60.1	59.9	58.2
	0.0	0.0	0.0	−6.4	0.0	0.0	0.0	0.0	0.0	0.0	2.3	−0.2
	56.4	37.5	48.8	47.3	57.5	43.9	44.9	52.5	51.5	44.6	43.6	43.8
	₹1.72	₹5.72	₹7.66	₹7.22	₹8.75	₹6.69	₹6.84	₹8.01	₹7.86	₹6.80	₹6.25	₹6.58

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

JLHL₹260.10

Jupiter Life Line Hospitals Ltd.

· Pharma & Health

Annual Quarterly₹ CrorePeersAPOLLOHOSP MAXHEALTH KIMS HCG MARKSANS METROPOLIS PARKHOSPS CORONAMcap ₹1,705 Cr

View

In ₹ Crore except Per Share 3 Months Ending	Q3 FY24 31/12/2023	Q4 FY24 31/03/2024	Q1 FY25 30/06/2024	Q2 FY25 30/09/2024	Q3 FY25 31/12/2024	Q4 FY25 31/03/2025	Q1 FY26 30/06/2025	Q2 FY26 30/09/2025	Q3 FY26 31/12/2025	Q4 FY26 31/03/2026	Q1 FY27 30/06/2026	Q2 FY27 30/09/2026
Revenue from Operations	272.6	290.5	287.1	322.6	320.6	326.7	347.6	393.6	365.4	387.8	411.0	456.5
Other Income	8.1	9.0	8.4	9.4	8.3	7.0	12.9	11.3	9.1	9.1	10.6	10.5
Total Income	280.7	299.4	295.5	332.0	328.9	333.8	360.5	404.9	374.5	397.0	421.6	467.0
Expenses
+ Purchases of Stock-in-Trade	48.4	53.4	53.6	59.6	60.3	59.5	68.7	74.5	76.7	76.8	79.7	84.3
+ Changes in Inventories	-0.3	-0.6	-3.3	0.4	-1.5	1.7	-0.4	-0.8	-7.7	-3.1	0.4	2.2
+ Employee Benefit Expense	50.1	51.5	51.3	53.9	55.5	53.8	59.4	63.2	63.6	67.7	74.5	81.3
+ Finance Costs	1.0	0.9	1.1	1.1	2.8	5.6	8.3	7.8	7.5	9.0	12.9	13.8
+ Depreciation & Amortisation	10.7	10.4	11.0	14.4	14.0	17.6	21.2	21.5	21.7	23.3	26.4	28.5
+ Other Expenses	112.5	124.0	121.8	133.7	131.3	133.5	141.7	164.4	149.2	157.2	177.2	181.8
Total Expenses	222.4	239.5	235.4	263.1	262.4	271.7	299.0	330.7	311.2	330.9	371.0	392.0
EBITDA	61.9	62.3	63.9	75.0	75.0	78.3	78.1	92.2	83.4	89.2	79.3	106.8
EBIT	51.2	51.9	52.9	60.6	61.0	60.6	56.9	70.8	61.7	65.9	52.8	78.4
Profit
PBT before Exceptional Items	58.2	59.9	60.1	68.9	66.6	62.1	61.5	74.2	63.3	66.0	50.6	75.1
+ Exceptional Items	-0.2	2.3	0.0	0.0	0.0	0.0	0.0	0.0	-6.4	0.0	0.0	0.0
Pretax Income	58.1	62.2	60.1	68.9	66.6	62.1	61.5	74.2	56.9	66.0	50.6	75.1
+ Current Tax	13.8	16.3	14.6	18.2	13.7	14.0	18.3	20.2	15.5	9.6	13.2	16.5
+ Deferred Tax	0.6	0.7	0.9	-0.8	0.4	3.2	-0.6	-3.5	-1.0	7.6	-0.1	2.2
Tax Expense	14.4	16.9	15.5	17.4	14.0	17.2	17.7	16.7	14.4	17.3	13.0	18.7
Net Income	43.7	45.3	44.6	51.5	52.5	44.9	43.9	57.5	42.5	48.8	37.5	56.4
+ Net Income — Continuing Ops	43.7	45.3	44.6	51.5	52.5	44.9	43.9	57.5	42.5	48.8	37.5	56.4
+ Other Comprehensive Income	0.0	-0.9	0.0	0.0	0.0	-1.2	0.0	0.0	0.0	1.9	0.0	-0.9
Total Comprehensive Income	43.7	44.4	44.6	51.5	52.5	43.7	43.9	57.5	42.5	50.7	37.5	55.5
Net Income to Common	—	—	44.6	51.5	—	44.9	43.8	57.4	42.6	50.6	37.5	56.2
Minority Interest	—	0.0	0.0	0.0	—	0.0	0.0	0.1	-0.1	0.1	0.0	0.2
Per Share
Basic EPS	6.56	6.49	6.80	7.86	8.01	6.84	6.69	8.75	6.49	7.66	5.72	1.72
Diluted EPS	6.56	6.49	6.80	7.86	8.01	6.84	6.69	8.75	6.49	7.66	5.72	1.72
Other Comprehensive Income — detail
+ Other Comprehensive Income	—	—	—	—	—	-1.2	—	0.0	0.0	1.9	0.0	-0.9
+ Items NOT to be Reclassified to P&L	0.0	-0.9	—	—	—	-1.6	—	—	—	—	—	-0.9
+ Tax on Items NOT to be Reclassified	—	—	—	—	—	-0.4	—	0.0	0.0	-1.9	0.0	0.0
Comprehensive Income — Owners of Parent	—	—	44.6	51.5	—	—	43.8	57.4	42.6	50.6	37.5	55.3
Comprehensive Income — Non-controlling Interests	—	—	0.0	0.0	—	—	0.0	0.1	-0.1	0.1	0.0	0.2
Per Share — as-filed variants
Basic EPS — Continuing Operations	6.56	6.49	6.80	7.86	8.01	6.84	6.69	8.75	6.49	7.66	5.72	1.72
Diluted EPS — Continuing Operations	6.56	6.49	6.80	7.86	8.01	6.84	6.69	8.75	6.49	7.66	5.72	1.72
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit	224.5	237.7	236.9	262.6	261.8	265.6	279.3	319.9	296.3	314.1	330.9	370.0
Gross Margin %	82.35	81.83	82.51	81.40	81.66	81.29	80.33	81.26	81.10	80.99	80.52	81.05
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)	58.2	59.9	60.1	68.9	66.6	62.1	61.5	74.2	63.3	66.0	50.6	75.1
− Exceptional Items (reconciliation)	-0.2	2.3	0.0	0.0	0.0	0.0	0.0	0.0	-6.4	0.0	0.0	0.0
Net Income Adj (tax-effected)	43.8	43.6	44.6	51.5	52.5	44.9	43.9	57.5	47.3	48.8	37.5	56.4
EPS Adj	6.58	6.25	6.80	7.86	8.01	6.84	6.69	8.75	7.22	7.66	5.72	1.72
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00	2.00
Paid Up Equity Capital	65.6	65.6	65.6	65.6	65.6	65.6	65.6	65.6	65.6	65.6	65.6	65.6

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: Q2 FY27 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.

Jupiter Life Line Hospitals Q2 FY27 results (July–September 2026)

Jupiter Life Line Hospitals (NSE: JLHL) reported its Q2 FY27 results (July–September 2026). Consolidated net profit was ₹56.2 crore, down 2.1% from ₹57.4 crore in Q2 FY26 and up 49.8% from ₹37.5 crore in Q1 FY27. Revenue from operations was ₹456 crore, up 16.0% year on year and up 11.1% from the previous quarter.

Q2 FY26 results (a year earlier): 7 November 2025
Q3 FY27 results due by: 14 February 2027

Q2 FY27 at a glance · consolidated

Net profit: ₹56.2 Cr−2.1% vs Q2 FY26+49.8% vs Q1 FY27
Revenue from operations: ₹456 Cr+16.0% vs Q2 FY26+11.1% vs Q1 FY27
Operating margin (EBIT): 17.2%−0.8 pts vs Q2 FY26+4.3 pts vs Q1 FY27EBIT ₹78.4 Cr
EBITDA: ₹107 Cr+15.8% vs Q2 FY26+34.8% vs Q1 FY27margin 23.4%
Earnings per share (basic): ₹1.72
Net profit margin: 12.3%−2.3 pts vs Q2 FY26+3.2 pts vs Q1 FY27

Questions

What was Jupiter Life Line Hospitals' net profit in Q2 FY27?

Consolidated net profit was ₹56.2 crore, down 2.1% from ₹57.4 crore in Q2 FY26 and up 49.8% from ₹37.5 crore in Q1 FY27.

What was Jupiter Life Line Hospitals' revenue in Q2 FY27?

Revenue from operations was ₹456 crore, up 16.0% year on year and up 11.1% from the previous quarter.

What was Jupiter Life Line Hospitals' operating margin in Q2 FY27?

Operating profit (EBIT — revenue less operating expenses, before finance costs and other income) was ₹78.4 crore, a margin of 17.2%, against 12.9% in Q1 FY27 and 18.0% in Q2 FY26. EBITDA was ₹107 crore, 23.4% of revenue.

How were Jupiter Life Line Hospitals' Q2 FY27 results?

Revenue grew from a year earlier while net profit fell: revenue was up 16.0% at ₹456 crore, and net profit was down 2.1% at ₹56.2 crore. The operating margin was 17.2%, down 0.8 percentage points from 18.0% a year earlier. Against Q1 FY27, net profit was up 49.8% and revenue up 11.1%.

How has Jupiter Life Line Hospitals' profit changed over the last four quarters?

Net profit by quarter: ₹42.6 crore in Q3 FY26, ₹50.6 crore in Q4 FY26, ₹37.5 crore in Q1 FY27 and ₹56.2 crore in Q2 FY27. That is ₹187 crore over the four quarters, down 5.9% from ₹199 crore in the four quarters before. Revenue from operations: ₹365 crore, ₹388 crore, ₹411 crore and ₹456 crore.

When will Jupiter Life Line Hospitals announce its Q3 FY27 results?

Q3 FY27 covers October–December 2026. Listed companies must publish quarterly results within 45 days of the quarter's end (SEBI listing rules, Regulation 33), so the results are due by 14 February 2027. The company tells the exchanges the date of the board meeting at least two working days before it.

What was Jupiter Life Line Hospitals' EPS in Q2 FY27?

Basic earnings per share were ₹1.72.

What was Jupiter Life Line Hospitals' net profit in the first half of FY27?

Consolidated net profit for the first half of FY27 (April–September 2026) was ₹93.7 crore, down 7.4% from ₹101 crore in the same months a year earlier. Revenue from operations was ₹867 crore, up 17.0%.

What is Jupiter Life Line Hospitals' net profit margin?

Jupiter Life Line Hospitals' net profit margin was 12.3% in Q2 FY27 (net profit as a share of revenue from operations), against 14.6% in Q2 FY26 (down 2.3 percentage points). For FY26 as a whole it was 13.0%.

What was Jupiter Life Line Hospitals' net profit in FY26?

Consolidated net profit was ₹194 crore in FY26 (April 2025–March 2026), up 0.6% from ₹193 crore in FY25. It was ₹177 crore in FY24 and ₹72.9 crore in FY23: up 166.7% over three years, 38.7% a year on average.

What was Jupiter Life Line Hospitals' revenue in FY26?

Revenue from operations was ₹1,500 crore in FY26 (April 2025–March 2026), up 18.9% from ₹1,262 crore in FY25. It was ₹1,070 crore in FY24 and ₹893 crore in FY23: up 68.0% over three years, 18.9% a year on average.

Where do these Jupiter Life Line Hospitals figures come from?

From Jupiter Life Line Hospitals' own consolidated results filings to NSE, in ₹ crore as filed. Growth compares the same consolidated figures a year and a quarter earlier.

Consolidated figures from the company's filings to NSE. Every company's results dates this season are in the Q2 FY27 results calendar, part of Alpha Plus.